Reply to: “Intraclass Difference in Pneumonia Risk with Fluticasone and Budesonide in COPD: A Systematic Review of Evidence from Direct-Comparison Studies” [Letter]

Detalles Bibliográficos
Autores principales: Barnes, Neil C, Singh, Dave, Lipson, David A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8121158/
https://www.ncbi.nlm.nih.gov/pubmed/34007169
http://dx.doi.org/10.2147/COPD.S304368
_version_ 1783692271297757184
author Barnes, Neil C
Singh, Dave
Lipson, David A
author_facet Barnes, Neil C
Singh, Dave
Lipson, David A
author_sort Barnes, Neil C
collection PubMed
description
format Online
Article
Text
id pubmed-8121158
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-81211582021-05-17 Reply to: “Intraclass Difference in Pneumonia Risk with Fluticasone and Budesonide in COPD: A Systematic Review of Evidence from Direct-Comparison Studies” [Letter] Barnes, Neil C Singh, Dave Lipson, David A Int J Chron Obstruct Pulmon Dis Letter Dove 2021-05-10 /pmc/articles/PMC8121158/ /pubmed/34007169 http://dx.doi.org/10.2147/COPD.S304368 Text en © 2021 Barnes et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Letter
Barnes, Neil C
Singh, Dave
Lipson, David A
Reply to: “Intraclass Difference in Pneumonia Risk with Fluticasone and Budesonide in COPD: A Systematic Review of Evidence from Direct-Comparison Studies” [Letter]
title Reply to: “Intraclass Difference in Pneumonia Risk with Fluticasone and Budesonide in COPD: A Systematic Review of Evidence from Direct-Comparison Studies” [Letter]
title_full Reply to: “Intraclass Difference in Pneumonia Risk with Fluticasone and Budesonide in COPD: A Systematic Review of Evidence from Direct-Comparison Studies” [Letter]
title_fullStr Reply to: “Intraclass Difference in Pneumonia Risk with Fluticasone and Budesonide in COPD: A Systematic Review of Evidence from Direct-Comparison Studies” [Letter]
title_full_unstemmed Reply to: “Intraclass Difference in Pneumonia Risk with Fluticasone and Budesonide in COPD: A Systematic Review of Evidence from Direct-Comparison Studies” [Letter]
title_short Reply to: “Intraclass Difference in Pneumonia Risk with Fluticasone and Budesonide in COPD: A Systematic Review of Evidence from Direct-Comparison Studies” [Letter]
title_sort reply to: “intraclass difference in pneumonia risk with fluticasone and budesonide in copd: a systematic review of evidence from direct-comparison studies” [letter]
topic Letter
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8121158/
https://www.ncbi.nlm.nih.gov/pubmed/34007169
http://dx.doi.org/10.2147/COPD.S304368
work_keys_str_mv AT barnesneilc replytointraclassdifferenceinpneumoniariskwithfluticasoneandbudesonideincopdasystematicreviewofevidencefromdirectcomparisonstudiesletter
AT singhdave replytointraclassdifferenceinpneumoniariskwithfluticasoneandbudesonideincopdasystematicreviewofevidencefromdirectcomparisonstudiesletter
AT lipsondavida replytointraclassdifferenceinpneumoniariskwithfluticasoneandbudesonideincopdasystematicreviewofevidencefromdirectcomparisonstudiesletter

Ejemplares similares